Ethosomal Gel Bearing Losartan 5% for Keloid Treatment

Launched by YUNI EKA ANGGRAINI · Jun 5, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for keloids, which are raised scars that can form after an injury or surgery. The study will compare the effectiveness of a gel containing a medication called losartan to a common injection treatment known as triamcinolone acetonide. Researchers will evaluate how well each treatment works by assessing the scars' appearance, color, size, and thickness, using a specific scoring system.

To participate in this trial, individuals must be at least 18 years old and have keloids that are at least 6 months old and cover an area of 25 square centimeters or more. Participants should not have received any other keloid treatments in the last two months. It’s important to note that people who are pregnant, have certain health conditions, or who may not understand the assessment process will not be eligible. Participants can expect to receive either the gel or the injection and will be monitored for how well their keloids respond to the treatment. This trial is currently not recruiting, but it’s aimed at finding a potentially better way to manage keloid scars.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • keloid patients who came to the outpatient clinic of general hospital Syafira Pekanbaru during 2023-2024,
• • age is greater than or equal to 18 year
• • keloid scar than or equal to 25 cm2
• • duration of keloids longer than or equal to 6 months
• • no drug interventions or not currently on keloid medications for the last two months.
• Exclusion Criteria:
• • subjects who do not understand the rubric of The patient and observer scar assessment scale (POSAS) and were not willing to participate
• • subjects with nodular keloids
• • subjects within antihypertensive therapy, pregnancy, malignancy, history of allergies, active skin lesions or bleeding in the keloid area.
• • subjects in the treatment of keloid within the last month.